Patents by Inventor Akira Kawada
Akira Kawada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11795172Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 24, 2021Date of Patent: October 24, 2023Assignee: Cardurion Pharmaceuticals, Inc.Inventors: Nobuyuki Matsunaga, Junya Shirai, Tomohiro Okawa, Yasufumi Miyamoto, Zenyu Shiokawa, Takashi Nakahata, Akito Shibuya, Akira Kawada, Malcolm MacCoss
-
Publication number: 20220098207Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 24, 2021Publication date: March 31, 2022Inventors: Nobuyuki MATSUNAGA, Junya SHIRAI, Tomohiro OKAWA, Yasufumi MIYAMOTO, Zenyu SHIOKAWA, Takashi NAKAHATA, Akito SHIBUYA, Akira KAWADA, Malcolm MACCOSS
-
Publication number: 20170114044Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0) wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: ApplicationFiled: December 13, 2016Publication date: April 27, 2017Inventors: Takahiko TANIGUCHI, Akira KAWADA, Mitsuyo KONDO, John F. QUINN, Jun KUNITOMO, Masato YOSHIKAWA, Makoto FUSHIMI
-
Publication number: 20150099757Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: ApplicationFiled: October 17, 2014Publication date: April 9, 2015Inventors: Takahiko TANIGUCHI, Akira KAWADA, Mitsuyo KONDO, John F. QUINN, Jun KUNITOMO, Masato YOSHIKAWA, Makoto FUSHIMI
-
Patent number: 8778944Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: GrantFiled: July 6, 2012Date of Patent: July 15, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiko Taniguchi, Akira Kawada, John F. Quinn, Jun Kunitomo, Masato Yoshikawa, Makoto Fushimi
-
Publication number: 20120277204Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: ApplicationFiled: July 6, 2012Publication date: November 1, 2012Inventors: Takahiko TANIGUCHI, Akira Kawada, Mitsuyo Kondo, John F. Quinn, Jun Kunitomo, Masato Yoshikawa, Makoto Fushimi
-
Publication number: 20120028951Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: ApplicationFiled: February 4, 2010Publication date: February 2, 2012Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takahiko Taniguchi, Akira Kawada, Mitsuyo Kondo, John F. Quinn, Jun Kunitomo, Masato Yoshikawa, Makoto Fushimi
-
Publication number: 20100197651Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: ApplicationFiled: February 4, 2010Publication date: August 5, 2010Inventors: Takahiko Taniguchi, Akira Kawada, Mitsuyo Kondo, John F. Quinn, Jun Kunitomo, Masato Yoshikawa, Makoto Fushimi
-
Patent number: 7767665Abstract: This invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.Type: GrantFiled: April 8, 2008Date of Patent: August 3, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Yutaka Nakayama, Akira Kawada, Haruhide Kimura, Taisuke Tawaraishi
-
Publication number: 20090082343Abstract: This invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.Type: ApplicationFiled: April 8, 2008Publication date: March 26, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Yutaka Nakayama, Akira Kawada, Haruhide Kimura, Taisuke Tawaraishi
-
Patent number: 7399759Abstract: This invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.Type: GrantFiled: September 2, 2002Date of Patent: July 15, 2008Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Kajino, Akira Kawada, Yutaka Nakayama, Haruhide Kimura, Taisuke Tawaraishi
-
Publication number: 20050032786Abstract: This invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.Type: ApplicationFiled: September 2, 2002Publication date: February 10, 2005Inventors: Masahiro Kajino, Akira Kawada, Yutaka Nakayama, Haruhide Kimura
-
Patent number: 5948754Abstract: A cyclic hexapeptide represented by the formula:cyclo?A--Asp(R.sup.1)--Y--NH--CHR.sup.2 --CO--C--D--Trp(N.sup.in --R.sup.3)--! (I)wherein A is a D-acidic-.alpha.-amino acid residue; Y is an acidic-.alpha.-amino acid residue; C is an L-.alpha.-amino acid residue; R.sup.1 is a group represented by the formula: ##STR1## wherein X.sup.1 and X.sup.2 are independently H, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or nitro, and may bind together to form a ring in cooperation with the adjacent carbon atom; R.sup.2 is C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-C.sub.1-3 alkyl, C.sub.1-6 alkylthio-C.sub.1-3 alkyl, C.sub.3-7 cycloalkylthio-C.sub.1-3 alkyl, C.sub.1-5 alkoxy-C.sub.1-3 alkyl, C.sub.3-7 cycloalkoxy-C.sub.1-3 alkyl, C.sub.1-6 alkylthio, C.sub.3-7 cycloalkylthio, C.sub.1-5 alkoxy or C.sub.3-7 cycloalkoxy; R.sup.3 is H, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, --COR.sup.4, --COOR.sup.5 or --CONHR.sup.6 ; when X.sup.1, X.sup.2 and R.sup.3 are all hydrogen atoms, R.sup.Type: GrantFiled: October 30, 1996Date of Patent: September 7, 1999Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuhiro Wakimasu, Takashi Kikuchi, Akira Kawada
-
Patent number: 5883075Abstract: Disclosed are (1) a cyclic hexapeptide represented by formula I or a salt thereof: ##STR1## wherein X and Y each represent .alpha.-amino acid residues, A represents a D-acidic-.alpha.-amino acid residue, B represents a neutral-.alpha.-amino acid residue, C represents an L-.alpha.-amino acid residue and D represents a D-.alpha.-amino acid residue having an aromatic ring group; and (2) a pharmaceutical composition comprising the peptide represented by formula I or a pharmaceutically aceptable salt thereof as an active ingredient.Type: GrantFiled: July 9, 1996Date of Patent: March 16, 1999Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuhiro Wakimasu, Takashi Kikuchi, Akira Kawada, Hideo Shirafuji
-
Patent number: 5616684Abstract: Cyclic peptides and their salts have antagonistic activity on endothelin receptors and antagonistic activity on NK2 receptors. The peptides have the formula ##STR1## wherein X and Y each represent .alpha.-amino acid residues, A represents a D-acidic-.alpha.-amino acid residue, B represents a neutral .alpha.-amino acid residue, C represents an L-.alpha.-amino acid residue and D represents a D-.alpha.-amino acid residue having an aromatic ring group; wherein hydroxy, thiol, amino, imino and carboxyl groups can be substituted or unsubstituted. Pharmaceutical compositions containing such peptides are also described.Type: GrantFiled: April 20, 1994Date of Patent: April 1, 1997Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuhiro Wakimasu, Takashi Kikuchi, Akira Kawada, Hideo Shirafuji
-
Patent number: 5330978Abstract: A phosphonic acid derivative compound represented by formula [I ] or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 each represent hydrocarbon groups which may be substituted, except cases in which (1) R.sub.2 is unsubstituted methyl, ( 2 ) R.sub.3 is an unsubstituted hydrocarbon group having 1 to 3 carbon atoms, and (3) R.sub.1 is benzyloxycarbonylaminomethyl, R.sub.2 is isobutyl and R.sub.3 is isobutyl or phenylmethyl, which has endothelin-converting enzyme inhibiting activity and is useful as pharmaceutical drugs such as therapeutic agents for hypertension, cardiac or cerebral circulatory diseases and renal diseases.Type: GrantFiled: June 3, 1992Date of Patent: July 19, 1994Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuhiro Wakimasu, Masaaki Mori, Akira Kawada
-
Patent number: 4787709Abstract: The invention relates to an optical fiber of the step-index type using quartz glass or an inorganic optical glass as the core material and a fluorine-containing resin as the cladding material. A copolymer of vinylidene fluoride with hexafluoroacetone, preferably at a molar ratio in the range from 96:4 to 88:12, is employed as the cladding material. Using such a copolymer, a highly transparent and very strong and tough cladding layer can easily be formed by a solution coating method.Type: GrantFiled: February 6, 1986Date of Patent: November 29, 1988Assignee: Central Glass Company, LimitedInventors: Akira Kawada, Takashi Yasumura, Toshio Koishi
-
Patent number: 4617350Abstract: A thermoplastic resin composition useful for optical purposes is obtained by blending a polymer of an acrylic ester with a copolymer of vinylidene fluoride (VDF) and hexafluoroacetone (HFA). The blending ratio is not limited, though very good transparency is ensured when the acrylic ester polymer amounts to at least 20 wt %. It is preferable to use a polymer of an acrylic ester with an alkyl alcohol having not more than 4 carbon atoms. When using the resin composition in optical fibers or cylindrical lenses it is suitable to use a VDF/HFA copolymer containing not more than 20 mol % of HFA. The refractive index of a member formed of the resin composition is lower than that of the acrylic ester polymer and falls in the range of about 1.37-1.48. The resin composition is soluble in various organic solvents and accordingly can be used for adhesing and coating purposes too. Besides, this resin composition serves as a thermochromic material.Type: GrantFiled: February 5, 1986Date of Patent: October 14, 1986Assignee: Central Glass Company, LimitedInventors: Kazuhiko Maeda, Akira Kawada
-
Patent number: RE35886Abstract: A phosphonic acid derivative compound represented by formula ?I ! or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 each represent hydrocarbon groups which may be substituted, except cases in which (1) R.sub.2 is unsubstituted methyl, ( 2 ) R.sub.3 is an unsubstituted hydrocarbon group having 1 to 3 carbon atoms, and (3) R.sub.1 is benzyloxycarbonylaminomethyl, R.sub.2 is isobutyl and R.sub.3 is isobutyl or phenylmethyl, which has endothelin-converting enzyme inhibiting activity and is useful as pharmaceutical drugs such as therapeutic agents for hypertension, cardiac or cerebral circulatory diseases and renal diseases.This is a Reissue of a Patent which was the subject of a Reexamination Certificate No. B1 5,330,978, dated Jun. 18, 1996, Request No. 90/00400, Oct. 18, 1995.Type: GrantFiled: July 12, 1996Date of Patent: September 1, 1998Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuhiro Wakimasu, Masaaki Mori, Akira Kawada